Showing 1 - 15 results of 15 for search 'Manisha Bhutani', query time: 0.05s
Refine Results
-
1
Mechanisms and management of CAR T toxicity by Christopher J. Ferreri, Manisha Bhutani
Published 2024-05-01
Article -
2
Management of paclitaxel-induced neurotoxicity by Manisha Bhutani, Philomena M. Colucci, Heather Laird-Fick, Barbara A. Conley
Published 2011-12-01
Article -
3
-
4
-
5
-
6
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study) by Hamid Ehsan, Myra Robinson, Peter M. Voorhees, Kristen Cassetta, Shanice Borden, Shebli Atrash, Manisha Bhutani, Cindy Varga, Mauricio Pineda-Roman, Reed Friend, Barry A. Paul
Published 2024-03-01
Article -
7
P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY by Manisha Bhutani, Alfred Garfall, Katarina Uttervall, Saad Z Usmani, Lionel Karlin, Lotfi Benboubker, Hareth Nahi, Jesús San Miguel, Danielle Trancucci, Keqin Qi, Tara Stephenson, Alfredo Perales-Puchalt, Katherine Chastain, Ajai Chari
Published 2023-08-01
Article -
8
Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma by David M. Foureau, Manisha Bhutani, Myra Robinson, Fei Guo, Duy Pham, Ben Buelow, Nury Steuerwald, Katherine Rigby, Elise Tjaden, Marina Leonidas, Barry A. Paul, Shebli Atrash, Ami Ndiaye, James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani
Published 2020-07-01
Article -
9
P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY by Carlyn Tan, Emma Searle, Sébastien Anguille, Manisha Bhutani, Noa Biran, Kevin Boyd, Andrew Cowan, Jeffrey Matous, Aurore Perrot, Jesus Berdeja, Wojciech Janowski, Rakesh Popat, Hang Quach, Mark Schroeder, Sandy W Wong, Deeksha Vishwamitra, Yue Guo, Zhuolu Niu, Julie Larsen, Lingling Chen, Arnob Banerjee, Cyrille Touzeau
Published 2023-08-01
Article -
10
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma by Manisha Bhutani, Myra Robinson, David Foureau, Shebli Atrash, Barry Paul, Fei Guo, Jason M. Grayson, Anna Ivanina-Foureau, Mauricio Pineda-Roman, Cindy Varga, Reed Friend, Christopher J. Ferreri, Xhevahire Begic, Sarah Norek, Tiffany Drennan, Michelle B. Anderson, James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani
Published 2025-02-01
Article -
11
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma by Neha Korde, Mattias Carlsten, Min-Jung Lee, Alex Minter, Esther Tan, Mary Kwok, Elisabet Manasanch, Manisha Bhutani, Nishant Tageja, Mark Roschewski, Adriana Zingone, Rene Costello, Marcia Mulquin, Diamond Zuchlinski, Irina Maric, Katherine R. Calvo, Raul Braylan, Prashant Tembhare, Constance Yuan, Maryalice Stetler-Stevenson, Jane Trepel, Richard Childs, Ola Landgren
Published 2014-06-01
Article -
12
P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) by Surbhi Sidana, Philippe Moreau, Alfred Garfall, Manisha Bhutani, Albert Oriol, Ajay Nooka, Tom Martin, Laura Rosiñol Dachs, Maria-Victoria Mateos, Nizar J Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martinez-Lopez, Amrita Krishnan, Michel Delforge, Danielle Trancucci, Raluca Verona, Tara Stephenson, Katherine Chastain, Niels W.C.J. van de Donk
Published 2023-08-01
Article -
13
S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS by Nizar J Bahlis, Katja Weisel, Maria-Victoria Mateos, Hartmut Goldschmidt, Tom Martin, Daniel Morillo, Donna Reece, Paula Rodríguez-Otero, Manisha Bhutani, Anita D’souza, Albert Oriol, Laura Rosiñol Dachs, Bhagirathbhai Dholaria, Kalpana Bakshi, Lijuan Kang, Lien Vandenberk, Damiette Smit, Ralph Wäsch, Niels W.C.J. van de Donk, Ajai Chari
Published 2023-08-01
Article -
14
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma by Sham Mailankody, Dickran Kazandjian, Neha Korde, Mark Roschewski, Elisabet Manasanch, Manisha Bhutani, Nishant Tageja, Mary Kwok, Yong Zhang, Adriana Zingone, Laurence Lamy, Rene Costello, Candis Morrison, Malin Hultcrantz, Austin Christofferson, Megan Washington, Martin Boateng, Seth M. Steinberg, Maryalice Stetler-Stevenson, William D. Figg, Elli Papaemmanuil, Wyndham H. Wilson, Jonathan J. Keats, Ola Landgren
Published 2017-10-01
Article -
15
P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY M... by Hermann Einsele, Philippe Moreau, Nizar J Bahlis, Manisha Bhutani, Laure Vincent, Lionel Karlin, Aurore Perrot, Hartmut Goldschmidt, Niels W.C.J. van de Donk, Enrique Ocio, Joaquín Martinez-Lopez, Paula Rodríguez-Otero, Dominik Dytfeld, Joris Diels, Vadim Strulev, Imene Haddad, Thomas Renaud, Eric Ammann, Jedelyn Cabrieto, Nolen Perualila, Ryan Gan, Youyi Zhang, Trilok Parekh, Claire Albrecht, Katja Weisel, Maria-Victoria Mateos
Published 2023-08-01
Article